Potential conflict of interest: Nothing to report.
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib
Version of Record online: 30 JUL 2013
© 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 3, pages 1065–1073, September 2013
How to Cite
Herraez, E., Lozano, E., Macias, R. I.R., Vaquero, J., Bujanda, L., Banales, J. M., Marin, J. J.G. and Briz, O. (2013), Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology, 58: 1065–1073. doi: 10.1002/hep.26425
Supported in part by the Junta de Castilla y Leon (Grants BIO39/SA27/10, SA023A11-2 and SA070A11-2), Spain; the Ministerio de Ciencia y Tecnologia (Grants SAF2009-08493 and SAF2010-15517), Spain; the Fundacion Investigacion Medica Mutua Madrileña (Call 2009), Spain, and Fundacion Samuel Solorzano Barruso (Grant FS/1-2011), Spain. E.L. was supported by the AP2008-0376 PhD grant from the Junta de Castilla y Leon/Fondo Social Europeo and J.V. by the AP2007-00105 PhD grant from the Ministerio de Educacion (AP2007-00105), Spain. J.M.B. and L.B. received grants from the Spanish Association Against Cancer (AECC), the Basque Department of Industry (Saiotek), and the Carlos III Health Institute, Spain (FIS grant PI12/00380).
- Issue online: 29 AUG 2013
- Version of Record online: 30 JUL 2013
- Accepted manuscript online: 26 MAR 2013 12:21PM EST
- Manuscript Accepted: 22 MAR 2013
- Manuscript Received: 30 NOV 2012
Additional Supporting Information may be found in the online version of this article.
|hep26425-sup-0001-suppfig1.tif||247K||Supporting Figure 1. Time-dependent effect of sorafenib. Two days after Alexander cells were transfected with wild-type OCT1 or empty vector (Mock) they were exposed to 5 µM sorafenib for the indicated time. Cell viability was determined 72 h after adding the sorafenib to the culture media. Values are means±SD from 4 experiments performed in triplicate. *, p<0.05, as compared with wild-type OCT1.|
|hep26425-sup-0002-supptab1.doc||61K||Supporting Table 1. Patient and tumor information|
|hep26425-sup-0003-supptab2.doc||45K||Supporting Table 2. Oligonucleotide sequence of specific primers for wild-type OCT1 or its variants used in this study.|
|hep26425-sup-0005-supptab4.doc||54K||Supporting Table 4. Screening of genetic variants affecting the coding sequence of OCT1 in cholangiocarcinoma (CGC) biopsies.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.